Agenus (AGEN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
16 Jun, 2026Opening remarks and agenda
Meeting called to order with board members and senior management present, confirming quorum and agenda as set in the proxy statement.
Inspector of Elections appointed and voting procedures explained, with six proposals on the agenda.
Board and executive committee updates
Election of Garo Armen and Jennifer Buell as Class 2 directors for a three-year term was proposed and carried.
Shareholder proposals
Amendments to the 2019 Employee Stock Purchase Plan and 2019 Equity Incentive Plan to increase share authorizations were proposed and carried.
Approval of a one-time stock option exchange program and a non-binding advisory vote on executive compensation for 2025 were carried.
Ratification of KPMG LLP as independent auditor for 2026 was approved.
Latest events from Agenus
- Registering 77.98M shares for resale after $85M private placement, with up to $255M more possible.AGEN
Registration filing - $38.6M net income and $85M funding drive pivotal ROBBIN trial in $7B MSS colon cancer market.AGEN
Q2 2026 - BOT + BAL shows unprecedented efficacy in MSS colon cancer, with a pivotal Phase 3 trial fully funded.AGEN
Corporate presentation - Biotech registers 2.1M shares for resale by investor; lead immunotherapy in Phase 3 trials.AGEN
Registration filing - $340M secured for pivotal Phase 3 BOT + BAL trial in MSS colon cancer, targeting $7B+ market.AGEN
Investor update - Zydus collaboration secures manufacturing and capital, enabling global BOT/BAL access expansion.AGEN
Status update - $91M Zydus deal boosts liquidity as BOT/BAL advances to Phase 3, but funding risks persist.AGEN
Q2 2025 - Strong BOT/BAL data, improved cash, but partnership losses raise going concern risks.AGEN
Q2 2024 - BOT/BAL shows strong efficacy as financials improve and capital proposals advance.AGEN
Q1 2025